SAS Output

23-FEB-2019 6:10

GI ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1613-mCRC, Adv/Met, TP vs CETIRI 1 Y 0 Screening 130 127 117 62 25 8 2 11/27/2017 361 142
            127 117 62 25 8 2      
 
    2 Y 1 Trastuzumab + Pertuzumab 130 10 10 6 5 2 0 11/27/2017    
        2 Cetuximab + Irinotecan   8 8 4 2 1 0      
            18 18 10 7 3 0      
 
    3 Y 3 Crossover: Trastuz + Pertuz 130 4 4 3 1 1 0 11/27/2017    
            4 4 3 1 1 0      
 
  S1815-Biliary, Met/LocAdv, GC+CPT±Nab-paclitaxel 1 Y 1 Gem+Cisplatin+Nab-paclitaxel 268 2 2 2 2 2 0 02/07/2019 98 44
        2 Gemcitabine + Cisplatin   1 1 1 1 1 1      
            3 3 3 3 3 1      
 
Yes A021502-Colon, Stg III, Chemo +/- Atezol, ATOMIC 1 E Total Registrations   10 10 4 3 0 0 03/23/2018 321 157
            10 10 4 3 0 0      
 
No A021501-Adeno Panc,Borderline Resect,Chemo vs ChemoRT 0 E Total Registrations   18 4 0 0 0 0 05/01/2017 28 15
            18 4 0 0 0 0      
 
    1 E Total Registrations   15 3 0 0 0 0 05/01/2017    
            15 3 0 0 0 0      
 
  EA2142-GI NEC, Adv G3, EP vs TMZ + CAP 1 E Total Registrations   4 0 0 0 0 0 07/14/2016 170 69
            4 0 0 0 0 0      
 
  EA2161-PANC, Adv Rapalog Resistant PNETs, MLN0128 1 E Total Registrations   1 1 1 0 0 0 09/06/2018 42 11
            1 1 1 0 0 0      
 
  EA2165-Anal, Stg II-III, Nivolumab after CMT 1 E Total Registrations   2 2 2 1 0 0 10/09/2018 69 33
            2 2 2 1 0 0      
 
    2 E Total Registrations   1 1 1 1 0 0 10/09/2018    
            1 1 1 1 0 0      
 
  NRGGI004-Colorectal, Stg IV, dMMR Immuno-Therapy 1 E Total Registrations   5 5 3 1 0 0 04/18/2018 268 117
            5 5 3 1 0 0